Results 1 to 10 of about 44,049 (242)
Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis
Frontiers in Immunology, 2022 Recurrent vulvovaginal candidiasis (RVVC) and vulvovaginal candidiasis (RVVC) are one of the most common gynecological infections, primarily caused by Candida species. Although risk factors of RVVC and VVC have been identified in many studies, antifungal
Gai Ge +6 more
doaj +4 more sources
Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
Journal of Investigative Medicine High Impact Case Reports, 2022 Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited.
Leah M. Grant MD, Robert Orenstein DO
doaj +4 more sources
Bacterial Vaginosis and Vulvovaginal Candidiasis Pathophysiologic Interrelationship [PDF]
MicroorganismsAmong the infectious causes of vulvovaginal symptoms, bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) dominate. Apart from infrequent mixed infections, both are considered independent and caused by unrelated pathogenic mechanisms.
Jack D. Sobel, Yogitha Sai Vempati
doaj +3 more sources
Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis
SAGE Open Medicine, 2022 Vulvovaginal candidiasis is a common infection associated most often with the overgrowth of the fungal species Candida albicans . Although most women will have at least one episode of vulvovaginal candidiasis in their lifetime, some will experience ...
Chemen M Neal, Mark G Martens
doaj +2 more sources
Treatment of Vulvovaginal Candidiasis-An Overview of Guidelines and the Latest Treatment Methods. [PDF]
J Clin Med, 2023 Vulvovaginal candidiasis (VVC) is a common condition associated with discomfort in affected women. Due to the presence of different forms of the disease, diverse treatment regimens are developed; the newest ones include oteseconazole and ibrexafungerp ...
Satora M +6 more
europepmc +2 more sources
Molecular association of Candida albicans and vulvovaginal candidiasis: focusing on a solution. [PDF]
Front Cell Infect Microbiol, 2023 Candida albicans-mediated vulvovaginal candidiasis (VVC) is a significant challenge in clinical settings, owing to the inefficacy of current antifungals in modulating virulence, development of resistance, and poor penetration into the biofilm matrix ...
David H, Solomon AP.
europepmc +2 more sources
Pathogens, 2023 Epidemiological data on women suffering from vulvovaginal candidiasis and its recurrence are outdated and vague. The aim of this study was to identify the prevalence of women diagnosed with vulvovaginal candidiasis, as well as the epidemiological profile
Encarnación Martínez-García +6 more
doaj +2 more sources
Phytotherapy of Vulvovaginal Candidiasis: A Narrative Review. [PDF]
Int J Mol SciVulvovaginal candidiasis (VVC) is a real gynecological problem among women of reproductive age from 15 to 49. A recent analysis showed that 75% of women will have an occurrence at least once per year, while 5% are observed to have recurrent vaginal ...
Picheta N +5 more
europepmc +2 more sources
Inflammatory cytokine signalling in vulvovaginal candidiasis: a hot mess driving immunopathology. [PDF]
Oxf Open ImmunolProtective immunity to opportunistic fungal infections consists of tightly regulated innate and adaptive immune responses that clear the infection. Immune responses to infections of the vaginal mucosa by Candida species are, however, an exception. In the
Cheng KO +4 more
europepmc +2 more sources
Risk factors for recurrent vulvovaginal candidiasis [PDF]
Vojnosanitetski Pregled, 2010 Background/Aim. Recurrent vulvovaginal candidiasis is relatively frequent condition, and may have serious health consequences, like chronic vulvovaginal pain syndrome. The aim of our study was to determine possible risk factors for recurrent vulvovaginal
Janković Slobodan +13 more
doaj +5 more sources